InsuLife

InsuLife is a Norwegian company aiming at developing and bringing the unparalleled investigational INS-2301 (earlier called LevellorTM) apply-on-the-skin based insulin to market. This includes the carrying out of any and all necessary product studies and authorization activities. INS-2301 will represent an international innovation and paradigm shift. Insulin in apply-on-the-skin form has the potential to fulfill a need for people with diabetes who want to avoid needles and to take insulin in the most practical way. There is no transdermal apply-on-the-skin insulin in the global pharmaceutical market today. InsuLife are developing a novel product with delivery of apply-on-the-skin insulin which will be easy form of administration and efficacy is expected to be comparable to the traditional subcutaneous injections. The Future of Insulin Delivery INS-2301 aims to be the first transdermal apply-on-the-skin Insulin. Applied directly onto the skin, INS-2301 eliminates the use of needle...